WOBURN, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/ARO2019?src=hash” target=”_blank”gt;#ARO2019lt;/agt;–Frequency
Therapeutics, a clinical-stage biotechnology company creating a new
class of drugs based on small molecule stimulation of dormant stem cells
within the body which we refer to as Progenitor Cell Activation (PCA),
today announced that the Company will present a podium presentation at
the upcoming 42nd Annual Mid-Winter Meeting of the
Association for Research in Otolaryngology (ARO) in Baltimore, MD,
taking place February 9-13, 2019.
Will McLean, Ph.D., Co-Founder and Vice President of Biology and
Regenerative Medicine at Frequency, will discuss new research
highlighting activation methods and the molecular underpinnings that
drive cochlear cell proliferation and regenerative behavior. Dr. McLean
will also co-moderate the Regeneration I session during the conference
which will take place on Monday, February 11 beginning at 10:30am ET.
Presentation details are as follows:
Title: Lgr5+ Cochlear Progenitor Cell Proliferation is Driven by
the Combined Activation of the Wnt, NonCanonical Notch, and PI3K Pathways
Abstract: PD 67
Date: Monday, February 11, 2019
Time: 11:00 – 11:15am ET
Location: Baltimore Marriott Waterfront
ABOUT PCA REGENERATION
Founded by pioneers in the field of regenerative medicine and drug
delivery technology, Frequency’s Progenitor Cell Activation (PCA)
Regeneration platform uses a combination of small molecules to stimulate
progenitor cells within the body to repair diseased or damaged tissue.
This technology enables native tissue regeneration without modifying
genes or removing cells from the body. This avoids the potential safety
risks of genetic engineering and the manufacturing challenges of
traditional cell therapy. This approach has been validated both in
animal and human cell models as well as in a human clinical trial with
the potential for broad application across many therapeutic areas.
ABOUT FREQUENCY THERAPEUTICS
Frequency Therapeutics develops small molecule drugs to stimulate cells
in the body to reverse biological deficits and restore healthy tissue.
Through the transitory activation of these cells, Frequency enables
disease modification without the complexity of genetic engineering. Our
ground-breaking therapy uses a proprietary combination of small-molecule
drugs that induce progenitor cells to multiply and create new cells.
While Frequency’s lead program targets hearing restoration, our PCA
Regeneration platform has the potential to touch upon a wide breadth of
disease indications. www.frequencytx.com.
Stefanie Tuck or Kari Watson
MacDougall Biomedical Communications